There are well-established disparities in cancer incidence and outcomes by race/ethnicity
that result from the interplay between structural, socioeconomic, socio-environmental …

Progress in the research and therapy of adult acute lymphoblastic leukemia (ALL) is
accelerating. This analysis summarizes the data derived from the clinical trials conducted at …

For over two decades, the EBMT has updated recommendations on indications for
haematopoietic cell transplantation (HCT) practice based on clinical and scientific …

Combining venetoclax, a selective BCL2 inhibitor, with low-dose navitoclax, a BCL-XL/BCL2
inhibitor, may allow targeting of both BCL2 and BCL-XL without dose-limiting …

Retrospective studies have suggested that older adolescents and young adults (AYAs) with
acute lymphoblastic leukemia (ALL) have better survival rates when treated using a pediatric …

Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL), also referred to as
BCR-ABL1–like ALL, is a high-risk subset with a gene expression profile that shares …

This manuscript represents a review of lymphoblastic leukemia/lymphoma (acute
lymphoblastic leukemia/lymphoblastic lymphoma), acute leukemias of ambiguous lineage …

Recent years have witnessed major advances that have improved outcome of adults with
acute lymphoblastic leukemia (ALL). The emergence of the concept of measurable residual …

Acute lymphoblastic leukemia (ALL) is the most successful paradigm of how risk-adapted
therapy and detailed understanding of the genetic alterations driving leukemogenesis and …

Genomic classification has improved risk assignment of pediatric, but not adult B-lineage
acute lymphoblastic leukemia (B-ALL). The international UKALLXII/ECOG-ACRIN E2993 (# …